German family-owned pain focused drugmaker Grünenthal has announced the pricing of 500 million-euro ($527.5 million) aggregate principal amount of 4.625% senior secured notes due 2031.

Galderma announces successful Phase III trial results for Nemluvio in treating prurigo nodularis, driving record trading ...

Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%.

Evotec's COO Craig Johnstone will leave by year-end as the company implements its Priority Reset restructuring amid declining ...

French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to ...

During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian ...

The waiting time for Latin American patients with cancer, central nervous system disorders or rare diseases can take up to ...

PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...

A report from DelveInsight highlights over 20 companies developing 22 treatments for myotonic dystrophy, with progress in ...

Olverembatinib, developed by Ascentage Pharma, will be added to China’s National Reimbursement Drug List (NRDL) starting next ...

The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa ...

The first iteration of the European Shortages Monitoring Platform (ESMP) has gone live. Using this version of the ESMP, marketing authorization holders (MAHs) can submit data to routinely report ...